Evidence map›Paper›PMID 8207835›Full record

ArticleJournal of virology1994

Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors.

S Valsesia-Wittmann, A Drynda, G Deléage, M Aumailley, J M Heard, O Danos, G Verdier, F L Cosset

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 115 citations in OpenAlex.

  1. Article
  2. The Impact of the CD9 Tetraspanin on Lentivirus Infectivity and Exosome Secretion.Molecular therapy : the journal of the American Society of Gene Therapy · 2018
    Article
  3. Article
  4. Lentiviral vectors for immune cells targeting.Immunopharmacology and immunotoxicology · 2010
    Review
  5. Article
  6. Article
  7. Article
  8. Targeting lentiviral vectors to specific cell types in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2006
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Retroviral membrane display of apoptotic effector molecules.Proceedings of the National Academy of Sciences of the United States of America · 2000
    Article
  19. Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types.Proceedings of the National Academy of Sciences of the United States of America · 1999
    Article
  20. Redirected infection of directly biotinylated recombinant adenovirus vectors through cell surface receptors and antigens.Proceedings of the National Academy of Sciences of the United States of America · 1999
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

S Valsesia-WittmannCGMC, CNRS UMR106, Université Claude Bernard Lyon-I, Villeurbanne.
A Drynda
G Deléage
M Aumailley
J M Heard
O Danos
G Verdier
F L Cosset
Université Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

On the basis of theoretical structural and comparative studies of various avian leukosis virus SU (surface) envelope proteins, we have identified four small regions (I, II, III, and IV) in their receptor-binding domains that could potentially be involved in binding to receptors. From the envelope gene of an avian leukosis virus of subgroup A, we have constructed a set of SU mutants in which these regions were replaced by the coding sequence of FLA16, a 16-amino-acid RGD-containing peptide known to be the target for several cellular integrin receptors. Helper-free retroviral particles carrying a neo-lacZ retroviral vector were produced with the mutant envelopes. SU mutants in which regions III and IV were substituted yielded normal levels of envelope precursors but were not detectably processed or incorporated in viral particles. In contrast, substitutions in regions I and II did not affect the processing and the viral incorporation of SU mutants. When FLA16 was inserted in region II, it could be detected with antibodies against FLA16 synthetic peptide, but only when viral particles were deglycosylated. Viral particles with envelopes mutated in region I or II were able to infect avian cells through the subgroup A receptor at levels similar to those of the wild type. When viruses with envelopes containing FLA16 peptide in region II were applied to plastic dishes, they were found to promote binding of mammalian cells resistant to infection by subgroup A avian leukosis viruses but expressing the integrins recognized by FLA16. Deglycosylated helper-free viruses obtained by mild treatment with N-glycosidase F have been used to infect these mammalian cells, and infections have been monitored by neomycin selection. No neomycin-resistant clones could be obtained after infection by viruses with wild-type envelopes. Conversely, colonies were obtained after infection by viruses with envelopes bearing FLA16 in region II, and the genome of the retroviral vector was found correctly integrated in cell DNA of these colonies. By using a blocking peptide containing the minimal adhesive RGD sequence contained in FLA16, we have shown that preincubation of target cells could specifically inhibit infection by viruses with FLA16.

Indexed as

Amino Acid SequenceAnimalsAvian Leukosis VirusBase SequenceBinding SitesGenetic VectorsHumansMolecular Sequence DataMutationOligodeoxyribonucleotidesRatsReceptors, VirusRecombinant Fusion ProteinsSequence Homology, Amino AcidTumor Cells, CulturedViral Envelope ProteinsOligodeoxyribonucleotidesReceptors, VirusRecombinant Fusion ProteinsViral Envelope Proteins

Identifiers

PMID8207835
PMCPMC236388
OpenAlexW1510346473

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.